The New York Times is releasing a series of data files with cumulative counts of coronavirus cases in the United States, at the state and county level, over time. We are compiling this time series data from state and local governments and health departments in an attempt to provide a complete record of the ongoing outbreak.

Since late January, The Times has tracked cases of coronavirus in real time as they were identified after testing. Because of the widespread shortage of testing, however, the data is necessarily limited in the picture it presents of the outbreak.

We have used this data to power our maps and reporting tracking the outbreak, and it is now being made available to the public in response to requests from researchers, scientists and government officials who would like access to the data to better understand the outbreak.

The data begins with the first reported coronavirus case in Washington State on Jan. 21, 2020. We will publish regular updates to the data in this repository.

As of 10/22/2020, this dataset is no longer being updated and has been replaced with a new dataset, which can be accessed here: https://data.ct.gov/Health-and-Human-Services/COVID-19-case-rate-per-100-000-population-and-perc/hree-nys2 This dataset includes the average daily COVID-19 case rate per 100,000 population by town over the last two MMWR weeks (https://wwwn.cdc.gov/nndss/document/MMWR_week_overview.pdf). These counts do not include cases among people residing in congregate settings, such as nursing homes, assisted living facilities, or correctional facilities. This dataset will be updated weekly.

From January 22 to May 30, 2020, the cumulative incidence rate of COVID-19 in the United States was highest among those aged 80 years and older. This statistic shows the estimated cumulative incidence rate of COVID-19 in the U.S. from January 22 to May 30, 2020, by age.

For further information about the coronavirus (COVID-19) pandemic, please visit our dedicated Facts and Figures page.

Data for CDC’s COVID Data Tracker site on Rates of COVID-19 Cases and Deaths by Vaccination Status. Click 'More' for important dataset description and footnotes

Dataset and data visualization details: These data were posted on October 21, 2022, archived on November 18, 2022, and revised on February 22, 2023. These data reflect cases among persons with a positive specimen collection date through September 24, 2022, and deaths among persons with a positive specimen collection date through September 3, 2022.

Vaccination status: A person vaccinated with a primary series had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after verifiably completing the primary series of an FDA-authorized or approved COVID-19 vaccine. An unvaccinated person had SARS-CoV-2 RNA or antigen detected on a respiratory specimen and has not been verified to have received COVID-19 vaccine. Excluded were partially vaccinated people who received at least one FDA-authorized vaccine dose but did not complete a primary series ≥14 days before collection of a specimen where SARS-CoV-2 RNA or antigen was detected. Additional or booster dose: A person vaccinated with a primary series and an additional or booster dose had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after receipt of an additional or booster dose of any COVID-19 vaccine on or after August 13, 2021. For people ages 18 years and older, data are graphed starting the week including September 24, 2021, when a COVID-19 booster dose was first recommended by CDC for adults 65+ years old and people in certain populations and high risk occupational and institutional settings. For people ages 12-17 years, data are graphed starting the week of December 26, 2021, 2 weeks after the first recommendation for a booster dose for adolescents ages 16-17 years. For people ages 5-11 years, data are included starting the week of June 5, 2022, 2 weeks after the first recommendation for a booster dose for children aged 5-11 years. For people ages 50 years and older, data on second booster doses are graphed starting the week including March 29, 2022, when the recommendation was made for second boosters. Vertical lines represent dates when changes occurred in U.S. policy for COVID-19 vaccination (details provided above). Reporting is by primary series vaccine type rather than additional or booster dose vaccine type. The booster dose vaccine type may be different than the primary series vaccine type. ** Because data on the immune status of cases and associated deaths are unavailable, an additional dose in an immunocompromised person cannot be distinguished from a booster dose. This is a relevant consideration because vaccines can be less effective in this group. Deaths: A COVID-19–associated death occurred in a person with a documented COVID-19 diagnosis who died; health department staff reviewed to make a determination using vital records, public health investigation, or other data sources. Rates of COVID-19 deaths by vaccination status are reported based on when the patient was tested for COVID-19, not the date they died. Deaths usually occur up to 30 days after COVID-19 diagnosis. Participating jurisdictions: Currently, these 31 health departments that regularly link their case surveillance to immunization information system data are included in these incidence rate estimates: Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Idaho, Indiana, Kansas, Kentucky, Louisiana, Massachusetts, Michigan, Minnesota, Nebraska, New Jersey, New Mexico, New York, New York City (New York), North Carolina, Philadelphia (Pennsylvania), Rhode Island, South Dakota, Tennessee, Texas, Utah, Washington, and West Virginia; 30 jurisdictions also report deaths among vaccinated and unvaccinated people. These jurisdictions represent 72% of the total U.S. population and all ten of the Health and Human Services Regions. Data on cases

Experimental estimates of the prevalence and duration of long COVID symptoms, and rates of adverse events for hospitalised coronavirus (COVID-19) patients compared with those for matched control patients.

The Sub-National COVID-19 Incidence and Determinants Dataset contains rich sub-national data on COVID-19 cases and deaths combined with data on factors associated with the spread and severity of COVID-19 outbreaks in 2020. The data covers 503 sub-national areas (NUTS-2 level and equivalents) of 46 countries in five continents (Europe, Asia, North America, South America and Oceania). Indicators were mostly gathered weekly, with the exception of some variables that are monthly and yearly. The dataset was compiled to study the determinants of COVID-19 outbreaks with a focus on the effects of international airline travel. However, the data are useful to investigate also other questions on the sub-national diffusion of COVID-19. The information used to build this dataset was drawn from a variety of sources in order to cover four major areas of interest: health outcomes of the pandemic (COVID-19 cases and deaths), international air travel (number of incoming air passengers, centrality of local airports in the global airline network and air travel limitation policies), population mixing and government policy responses, and pre-pandemic area characteristics (socioeconomic, demographic, public health and co-morbidity). A complete list of sources can be found in the “Data sources” Pdf document attached.

Please cite as: Recchi, E., A. Ferrara, A. Rodríguez Sánchez, E. Deutschmann, L. Gabrielli, S. Iacus, L. Bastiani, S. Spyratos & M. Vespe. 2022. The Impact of Air Travel on the Precocity and Severity of Covid-19 Deaths in Sub-National Areas across 45 Countries. Scientific Reports 12: 16522. https://doi.org/10.1038/s41598-022-20263-y

From January 22 to May 30, 2020, the cumulative incidence rate of COVID-19 in the United States was slightly higher among females than males. This statistic shows the estimated cumulative incidence rate of COVID-19 in the U.S. from January 22 to May 30, 2020, by age and gender.

For further information about the coronavirus (COVID-19) pandemic, please visit our dedicated Facts and Figures page.

This dataset contains information on antibody testing for COVID-19: the number of people who received a test, the number of people with positive results, the percentage of people tested who tested positive, and the rate of testing per 100,000 people, stratified by week of testing. These data can also be accessed here: https://github.com/nychealth/coronavirus-data/blob/master/trends/antibody-by-week.csv Exposure to COVID-19 can be detected by measuring antibodies to the disease in a person’s blood, which can indicate that a person may have had an immune response to the virus. Antibodies are proteins produced by the body’s immune system that can be found in the blood. People can test positive for antibodies after they have been exposed, sometimes when they no longer test positive for the virus itself. It is important to note that the science around COVID-19 antibody tests is evolving rapidly and there is still much uncertainty about what individual antibody test results mean for a single person and what population-level antibody test results mean for understanding the epidemiology of COVID-19 at a population level. These data only provide information on people tested. People receiving an antibody test do not reflect all people in New York City; therefore, these data may not reflect antibody prevalence among all New Yorkers. Increasing instances of screening programs further impact the generalizability of these data, as screening programs influence who and how many people are tested over time. Examples of screening programs in NYC include: employers screening their workers (e.g., hospitals), and long-term care facilities screening their residents. In addition, there may be potential biases toward people receiving an antibody test who have a positive result because people who were previously ill are preferentially seeking testing, in addition to the testing of persons with higher exposure (e.g., health care workers, first responders.) Rates were calculated using interpolated intercensal population estimates updated in 2019. These rates differ from previously reported rates based on the 2000 Census or previous versions of population estimates. The Health Department produced these population estimates based on estimates from the U.S. Census Bureau and NYC Department of City Planning. Antibody tests are categorized based on the date of specimen collection and are aggregated by full weeks starting each Sunday and ending on Saturday. For example, a person whose blood was collected for antibody testing on Wednesday, May 6 would be categorized as tested during the week ending May 9. A person tested twice in one week would only be counted once in that week. This dataset includes testing data beginning April 5, 2020. Data are updated daily, and the dataset preserves historical records and source data changes, so each extract date reflects the current copy of the data as of that date. For example, an extract date of 11/04/2020 and extract date of 11/03/2020 will both contain all records as they were as of that extract date. Without filtering or grouping by extract date, an analysis will almost certainly be miscalculating or counting the same values multiple times. To analyze the most current data, only use the latest extract date. Antibody tests that are missing dates are not included in the dataset; as dates are identified, these events are added. Lags between occurrence and report of cases and tests can be assessed by comparing counts and rates across multiple data extract dates. For further details, visit: • https://www1.nyc.gov/site/doh/covid/covid-19-data.page • https://github.com/nychealth/coronavirus-data

Actions of Public Health France Public Health France’s mission is to improve and protect the health of populations. During the health crisis linked to the COVID-19 outbreak, Santé publique France is responsible for monitoring and understanding the dynamics of the epidemic, anticipating the various scenarios and putting in place actions to prevent and limit the transmission of this virus on national territory. ### The Tracking Information System (SI-DEP) The new screening information system (SI-DEP), which has been in operation since 13 May 2020, is a secure platform where the results of the laboratory tests carried out by all city and hospital laboratories for SARS-COV2 are systematically recorded. The creation of this information system is authorised for a period of 6 months from the end of the state of health emergency by application of Decree No 2020-551 of 12 May 2020 on the information systems referred to in Article 11 of Law No 2020-546 of 11 May 2020 extending the state of health emergency and supplementing its provisions. ### Description of data This dataset provides information at the departmental and regional level: — the daily and weekly incidence rate per age group; — the daily and weekly standardised incidence rate; — the sliding standardised incidence rate. This dataset provides information at the national level: — the daily and weekly incidence rate by age group and sex; — the daily and weekly standardised incidence rate; — the sliding standardised incidence rate. The incidence rate corresponds to the number of positive tests per 100,000 inhabitants. It shall be calculated as follows: (100000 * number of positive cases)/Population Accuracy: — From 29/08 onwards, laboratory data indicators (SI-DEP) show rates of incidence, positivity and screening adjusted for screenings conducted at airports upon arrival of international flights. — For more information, see the methodological note available in the resources. Limits: — Only the biological tests of persons for whom the residence department could be located are shown on the maps. Persons whose department could not be traced in the SIDEP data are counted only at the whole French level. As a result, the sum of the tests indicated in the departments or regions is less than the number of tests indicated in France. — The time limit for repeating tests may exceed 9 days in some cases. The indicators are adjusted daily according to the receipt of the results. ### Notable changes Since 8 December, after verifying the quality of the reported data, all results of RT-PCR or Antigenic tests have been included in the production of national and territorial epidemiological indicators (incidence rates, positivity rates and screening rates) relevant to the monitoring of the COVID-19 outbreak. On the other hand, the epidemic is prolonging in time and screening capacities have increased, leading to an increasing frequency of people tested several times. Thus, an adjustment of the methods of splitting for patients benefiting from repeated tests and therefore the definition of the persons tested was necessary. Public Health France, in its patient-centred epidemiological approach, has therefore adapted its methods to ensure that these indicators reflect, in particular, the proportion of infected people among the population tested. These developments have no impact on the trends and interpretation of the dynamics of the epidemic, which remain the same. More precise test data (impact and positivity) are also published by Santé publique France (SI-DEP data).

Reporting of new Aggregate Case and Death Count data was discontinued May 11, 2023, with the expiration of the COVID-19 public health emergency declaration. This dataset will receive a final update on June 1, 2023, to reconcile historical data through May 10, 2023, and will remain publicly available.

Aggregate Data Collection Process Since the start of the COVID-19 pandemic, data have been gathered through a robust process with the following steps:

• A CDC data team reviews and validates the information obtained from jurisdictions’ state and local websites via an overnight data review process.
• If more than one official county data source exists, CDC uses a comprehensive data selection process comparing each official county data source, and takes the highest case and death counts respectively, unless otherwise specified by the state.
• CDC compiles these data and posts the finalized information on COVID Data Tracker.
• County level data is aggregated to obtain state and territory specific totals.

This process is collaborative, with CDC and jurisdictions working together to ensure the accuracy of COVID-19 case and death numbers. County counts provide the most up-to-date numbers on cases and deaths by report date. CDC may retrospectively update counts to correct data quality issues.

Methodology Changes Several differences exist between the current, weekly-updated dataset and the archived version:

• Source: The current Weekly-Updated Version is based on county-level aggregate count data, while the Archived Version is based on State-level aggregate count data.
• Confirmed/Probable Cases/Death breakdown:  While the probable cases and deaths are included in the total case and total death counts in both versions (if applicable), they were reported separately from the confirmed cases and deaths by jurisdiction in the Archived Version.  In the current Weekly-Updated Version, the counts by jurisdiction are not reported by confirmed or probable status (See Confirmed and Probable Counts section for more detail).
• Time Series Frequency: The current Weekly-Updated Version contains weekly time series data (i.e., one record per week per jurisdiction), while the Archived Version contains daily time series data (i.e., one record per day per jurisdiction).
• Update Frequency: The current Weekly-Updated Version is updated weekly, while the Archived Version was updated twice daily up to October 20, 2022.

Important note: The counts reflected during a given time period in this dataset may not match the counts reflected for the same time period in the archived dataset noted above. Discrepancies may exist due to differences between county and state COVID-19 case surveillance and reconciliation efforts.

Confirmed and Probable Counts In this dataset, counts by jurisdiction are not displayed by confirmed or probable status. Instead, confirmed and probable cases and deaths are included in the Total Cases and Total Deaths columns, when available. Not all jurisdictions report probable cases and deaths to CDC.* Confirmed and probable case definition criteria are described here:

Council of State and Territorial Epidemiologists (ymaws.com).

Deaths CDC reports death data on other sections of the website: CDC COVID Data Tracker: Home, CDC COVID Data Tracker: Cases, Deaths, and Testing, and NCHS Provisional Death Counts. Information presented on the COVID Data Tracker pages is based on the same source (total case counts) as the present dataset; however, NCHS Death Counts are based on death certificates that use information reported by physicians, medical examiners, or coroners in the cause-of-death section of each certificate. Data from each of these pages are considered provisional (not complete and pending verification) and are therefore subject to change. Counts from previous weeks are continually revised as more records are received and processed.

Number of Jurisdictions Reporting There are currently 60 public health jurisdictions reporting cases of COVID-19. This includes the 50 states, the District of Columbia, New York City, the U.S. territories of American Samoa, Guam, the Commonwealth of the Northern Mariana Islands, Puerto Rico, and the U.S Virgin Islands as well as three independent countries in compacts of free association with the United States, Federated States of Micronesia, Republic of the Marshall Islands, and Republic of Palau. New York State’s reported case and death counts do not include New York City’s counts as they separately report nationally notifiable conditions to CDC.

CDC COVID-19 data are available to the public as summary or aggregate count files, including total counts of cases and deaths, available by state and by county. These and other data on COVID-19 are available from multiple public locations, such as:

https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/cases-in-us.html

https://www.cdc.gov/covid-data-tracker/index.html

https://www.cdc.gov/coronavirus/2019-ncov/covid-data/covidview/index.html

https://www.cdc.gov/coronavirus/2019-ncov/php/open-america/surveillance-data-analytics.html

Additional COVID-19 public use datasets, include line-level (patient-level) data, are available at: https://data.cdc.gov/browse?tags=covid-19.

Archived Data Notes:

November 3, 2022: Due to a reporting cadence issue, case rates for Missouri counties are calculated based on 11 days’ worth of case count data in the Weekly United States COVID-19 Cases and Deaths by State data released on November 3, 2022, instead of the customary 7 days’ worth of data.

November 10, 2022: Due to a reporting cadence change, case rates for Alabama counties are calculated based on 13 days’ worth of case count data in the Weekly United States COVID-19 Cases and Deaths by State data released on November 10, 2022, instead of the customary 7 days’ worth of data.

November 10, 2022: Per the request of the jurisdiction, cases and deaths among non-residents have been removed from all Hawaii county totals throughout the entire time series. Cumulative case and death counts reported by CDC will no longer match Hawaii’s COVID-19 Dashboard, which still includes non-resident cases and deaths. 

November 17, 2022: Two new columns, weekly historic cases and weekly historic deaths, were added to this dataset on November 17, 2022. These columns reflect case and death counts that were reported that week but were historical in nature and not reflective of the current burden within the jurisdiction. These historical cases and deaths are not included in the new weekly case and new weekly death columns; however, they are reflected in the cumulative totals provided for each jurisdiction. These data are used to account for artificial increases in case and death totals due to batched reporting of historical data.

December 1, 2022: Due to cadence changes over the Thanksgiving holiday, case rates for all Ohio counties are reported as 0 in the data released on December 1, 2022.

January 5, 2023: Due to North Carolina’s holiday reporting cadence, aggregate case and death data will contain 14 days’ worth of data instead of the customary 7 days. As a result, case and death metrics will appear higher than expected in the January 5, 2023, weekly release.

January 12, 2023: Due to data processing delays, Mississippi’s aggregate case and death data will be reported as 0. As a result, case and death metrics will appear lower than expected in the January 12, 2023, weekly release.

January 19, 2023: Due to a reporting cadence issue, Mississippi’s aggregate case and death data will be calculated based on 14 days’ worth of data instead of the customary 7 days in the January 19, 2023, weekly release.

January 26, 2023: Due to a reporting backlog of historic COVID-19 cases, case rates for two Michigan counties (Livingston and Washtenaw) were higher than expected in the January 19, 2023 weekly release.

January 26, 2023: Due to a backlog of historic COVID-19 cases being reported this week, aggregate case and death counts in Charlotte County and Sarasota County, Florida, will appear higher than expected in the January 26, 2023 weekly release.

January 26, 2023: Due to data processing delays, Mississippi’s aggregate case and death data will be reported as 0 in the weekly release posted on January 26, 2023.

February 2, 2023: As of the data collection deadline, CDC observed an abnormally large increase in aggregate COVID-19 cases and deaths reported for Washington State. In response, totals for new cases and new deaths released on February 2, 2023, have been displayed as zero at the state level until the issue is addressed with state officials. CDC is working with state officials to address the issue.

February 2, 2023: Due to a decrease reported in cumulative case counts by Wyoming, case rates will be reported as 0 in the February 2, 2023, weekly release. CDC is working with state officials to verify the data submitted.

February 16, 2023: Due to data processing delays, Utah’s aggregate case and death data will be reported as 0 in the weekly release posted on February 16, 2023. As a result, case and death metrics will appear lower than expected and should be interpreted with caution.

February 16, 2023: Due to a reporting cadence change, Maine’s

As of December 12, 2022, Hong Kong had the highest rate of coronavirus (COVID-19) cases reported in the previous seven days in the Asia-Pacific region, around 1.19 thousand cases per 100 thousand people. South Korea followed with 825 cases per 100,000 people in the past seven days.

Reporting of Aggregate Case and Death Count data was discontinued May 11, 2023, with the expiration of the COVID-19 public health emergency declaration. Although these data will continue to be publicly available, this dataset will no longer be updated.

This archived public use dataset has 11 data elements reflecting United States COVID-19 community levels for all available counties.

The COVID-19 community levels were developed using a combination of three metrics — new COVID-19 admissions per 100,000 population in the past 7 days, the percent of staffed inpatient beds occupied by COVID-19 patients, and total new COVID-19 cases per 100,000 population in the past 7 days. The COVID-19 community level was determined by the higher of the new admissions and inpatient beds metrics, based on the current level of new cases per 100,000 population in the past 7 days. New COVID-19 admissions and the percent of staffed inpatient beds occupied represent the current potential for strain on the health system. Data on new cases acts as an early warning indicator of potential increases in health system strain in the event of a COVID-19 surge.

Using these data, the COVID-19 community level was classified as low, medium, or high.

COVID-19 Community Levels were used to help communities and individuals make decisions based on their local context and their unique needs. Community vaccination coverage and other local information, like early alerts from surveillance, such as through wastewater or the number of emergency department visits for COVID-19, when available, can also inform decision making for health officials and individuals.

For the most accurate and up-to-date data for any county or state, visit the relevant health department website. COVID Data Tracker may display data that differ from state and local websites. This can be due to differences in how data were collected, how metrics were calculated, or the timing of web updates.

Archived Data Notes:

This dataset was renamed from "United States COVID-19 Community Levels by County as Originally Posted" to "United States COVID-19 Community Levels by County" on March 31, 2022.

March 31, 2022: Column name for county population was changed to “county_population”. No change was made to the data points previous released.

March 31, 2022: New column, “health_service_area_population”, was added to the dataset to denote the total population in the designated Health Service Area based on 2019 Census estimate.

March 31, 2022: FIPS codes for territories American Samoa, Guam, Commonwealth of the Northern Mariana Islands, and United States Virgin Islands were re-formatted to 5-digit numeric for records released on 3/3/2022 to be consistent with other records in the dataset.

March 31, 2022: Changes were made to the text fields in variables “county”, “state”, and “health_service_area” so the formats are consistent across releases.

March 31, 2022: The “%” sign was removed from the text field in column “covid_inpatient_bed_utilization”. No change was made to the data. As indicated in the column description, values in this column represent the percentage of staffed inpatient beds occupied by COVID-19 patients (7-day average).

March 31, 2022: Data values for columns, “county_population”, “health_service_area_number”, and “health_service_area” were backfilled for records released on 2/24/2022. These columns were added since the week of 3/3/2022, thus the values were previously missing for records released the week prior.

April 7, 2022: Updates made to data released on 3/24/2022 for Guam, Commonwealth of the Northern Mariana Islands, and United States Virgin Islands to correct a data mapping error.

April 21, 2022: COVID-19 Community Level (CCL) data released for counties in Nebraska for the week of April 21, 2022 have 3 counties identified in the high category and 37 in the medium category. CDC has been working with state officials to verify the data submitted, as other data systems are not providing alerts for substantial increases in disease transmission or severity in the state.

May 26, 2022: COVID-19 Community Level (CCL) data released for McCracken County, KY for the week of May 5, 2022 have been updated to correct a data processing error. McCracken County, KY should have appeared in the low community level category during the week of May 5, 2022. This correction is reflected in this update.

May 26, 2022: COVID-19 Community Level (CCL) data released for several Florida counties for the week of May 19th, 2022, have been corrected for a data processing error. Of note, Broward, Miami-Dade, Palm Beach Counties should have appeared in the high CCL category, and Osceola County should have appeared in the medium CCL category. These corrections are reflected in this update.

May 26, 2022: COVID-19 Community Level (CCL) data released for Orange County, New York for the week of May 26, 2022 displayed an erroneous case rate of zero and a CCL category of low due to a data source error. This county should have appeared in the medium CCL category.

June 2, 2022: COVID-19 Community Level (CCL) data released for Tolland County, CT for the week of May 26, 2022 have been updated to correct a data processing error. Tolland County, CT should have appeared in the medium community level category during the week of May 26, 2022. This correction is reflected in this update.

June 9, 2022: COVID-19 Community Level (CCL) data released for Tolland County, CT for the week of May 26, 2022 have been updated to correct a misspelling. The medium community level category for Tolland County, CT on the week of May 26, 2022 was misspelled as “meduim” in the data set. This correction is reflected in this update.

June 9, 2022: COVID-19 Community Level (CCL) data released for Mississippi counties for the week of June 9, 2022 should be interpreted with caution due to a reporting cadence change over the Memorial Day holiday that resulted in artificially inflated case rates in the state.

July 7, 2022: COVID-19 Community Level (CCL) data released for Rock County, Minnesota for the week of July 7, 2022 displayed an artificially low case rate and CCL category due to a data source error. This county should have appeared in the high CCL category.

July 14, 2022: COVID-19 Community Level (CCL) data released for Massachusetts counties for the week of July 14, 2022 should be interpreted with caution due to a reporting cadence change that resulted in lower than expected case rates and CCL categories in the state.

July 28, 2022: COVID-19 Community Level (CCL) data released for all Montana counties for the week of July 21, 2022 had case rates of 0 due to a reporting issue. The case rates have been corrected in this update.

July 28, 2022: COVID-19 Community Level (CCL) data released for Alaska for all weeks prior to July 21, 2022 included non-resident cases. The case rates for the time series have been corrected in this update.

July 28, 2022: A laboratory in Nevada reported a backlog of historic COVID-19 cases. As a result, the 7-day case count and rate will be inflated in Clark County, NV for the week of July 28, 2022.

August 4, 2022: COVID-19 Community Level (CCL) data was updated on August 2, 2022 in error during performance testing. Data for the week of July 28, 2022 was changed during this update due to additional case and hospital data as a result of late reporting between July 28, 2022 and August 2, 2022. Since the purpose of this data set is to provide point-in-time views of COVID-19 Community Levels on Thursdays, any changes made to the data set during the August 2, 2022 update have been reverted in this update.

August 4, 2022: COVID-19 Community Level (CCL) data for the week of July 28, 2022 for 8 counties in Utah (Beaver County, Daggett County, Duchesne County, Garfield County, Iron County, Kane County, Uintah County, and Washington County) case data was missing due to data collection issues. CDC and its partners have resolved the issue and the correction is reflected in this update.

August 4, 2022: Due to a reporting cadence change, case rates for all Alabama counties will be lower than expected. As a result, the CCL levels published on August 4, 2022 should be interpreted with caution.

August 11, 2022: COVID-19 Community Level (CCL) data for the week of August 4, 2022 for South Carolina have been updated to correct a data collection error that resulted in incorrect case data. CDC and its partners have resolved the issue and the correction is reflected in this update.

August 18, 2022: COVID-19 Community Level (CCL) data for the week of August 11, 2022 for Connecticut have been updated to correct a data ingestion error that inflated the CT case rates. CDC, in collaboration with CT, has resolved the issue and the correction is reflected in this update.

August 25, 2022: A laboratory in Tennessee reported a backlog of historic COVID-19 cases. As a result, the 7-day case count and rate may be inflated in many counties and the CCLs published on August 25, 2022 should be interpreted with caution.

August 25, 2022: Due to a data source error, the 7-day case rate for St. Louis County, Missouri, is reported as zero in the COVID-19 Community Level data released on August 25, 2022. Therefore, the COVID-19 Community Level for this county should be interpreted with caution.

September 1, 2022: Due to a reporting issue, case rates for all Nebraska counties will include 6 days of data instead of 7 days in the COVID-19 Community Level (CCL) data released on September 1, 2022. Therefore, the CCLs for all Nebraska counties should be interpreted with caution.

September 8, 2022: Due to a data processing error, the case rate for Philadelphia County, Pennsylvania,

Estimates of the prevalence of self-reported long COVID and associated activity limitation, using UK Coronavirus (COVID-19) Infection Survey data. Experimental Statistics.

Covid-19 incidence from multiple sources for comparison in a chart

The COVID-19 dashboard includes data on city/town COVID-19 activity, confirmed and probable cases of COVID-19, confirmed and probable deaths related to COVID-19, and the demographic characteristics of cases and deaths.

Provisional count of deaths involving coronavirus disease 2019 (COVID-19) by United States county of occurrence, from January 1, 2020 through December 31, 2020.

NOTE: This dataset has been retired and marked as historical-only. Weekly rates of COVID-19 cases, hospitalizations, and deaths among people living in Chicago by vaccination status and age. Rates for fully vaccinated and unvaccinated begin the week ending April 3, 2021 when COVID-19 vaccines became widely available in Chicago. Rates for boosted begin the week ending October 23, 2021 after booster shots were recommended by the Centers for Disease Control and Prevention (CDC) for adults 65+ years old and adults in certain populations and high risk occupational and institutional settings who received Pfizer or Moderna for their primary series or anyone who received the Johnson & Johnson vaccine. Chicago residency is based on home address, as reported in the Illinois Comprehensive Automated Immunization Registry Exchange (I-CARE) and Illinois National Electronic Disease Surveillance System (I-NEDSS). Outcomes: • Cases: People with a positive molecular (PCR) or antigen COVID-19 test result from an FDA-authorized COVID-19 test that was reported into I-NEDSS. A person can become re-infected with SARS-CoV-2 over time and so may be counted more than once in this dataset. Cases are counted by week the test specimen was collected. • Hospitalizations: COVID-19 cases who are hospitalized due to a documented COVID-19 related illness or who are admitted for any reason within 14 days of a positive SARS-CoV-2 test. Hospitalizations are counted by week of hospital admission. • Deaths: COVID-19 cases who died from COVID-19-related health complications as determined by vital records or a public health investigation. Deaths are counted by week of death. Vaccination status: • Fully vaccinated: Completion of primary series of a U.S. Food and Drug Administration (FDA)-authorized or approved COVID-19 vaccine at least 14 days prior to a positive test (with no other positive tests in the previous 45 days). • Boosted: Fully vaccinated with an additional or booster dose of any FDA-authorized or approved COVID-19 vaccine received at least 14 days prior to a positive test (with no other positive tests in the previous 45 days). • Unvaccinated: No evidence of having received a dose of an FDA-authorized or approved vaccine prior to a positive test. CLARIFYING NOTE: Those who started but did not complete all recommended doses of an FDA-authorized or approved vaccine prior to a positive test (i.e., partially vaccinated) are excluded from this dataset. Incidence rates for fully vaccinated but not boosted people (Vaccinated columns) are calculated as total fully vaccinated but not boosted with outcome divided by cumulative fully vaccinated but not boosted at the end of each week. Incidence rates for boosted (Boosted columns) are calculated as total boosted with outcome divided by cumulative boosted at the end of each week. Incidence rates for unvaccinated (Unvaccinated columns) are calculated as total unvaccinated with outcome divided by total population minus cumulative boosted, fully, and partially vaccinated at the end of each week. All rates are multiplied by 100,000. Incidence rate ratios (IRRs) are calculated by dividing the weekly incidence rates among unvaccinated people by those among fully vaccinated but not boosted and boosted people. Overall age-adjusted incidence rates and IRRs are standardized using the 2000 U.S. Census standard population. Population totals are from U.S. Census Bureau American Community Survey 1-year estimates for 2019. All data are provisional and subject to change. Information is updated as additional details are received and it is, in fact, very common for recent dates to be incomplete and to be updated as time goes on. This dataset reflects data known to CDPH at the time when the dataset is updated each week. Numbers in this dataset may differ from other public sources due to when data are reported and how City of Chicago boundaries are defined. For all datasets related to COVID-19, see https://data.cityofchic

Data for CDC’s COVID Data Tracker site on Rates of COVID-19 Cases and Deaths by Updated (Bivalent) Booster Status. Click 'More' for important dataset description and footnotes

Webpage: https://covid.cdc.gov/covid-data-tracker/#rates-by-vaccine-status

Dataset and data visualization details:

These data were posted and archived on May 30, 2023 and reflect cases among persons with a positive specimen collection date through April 22, 2023, and deaths among persons with a positive specimen collection date through April 1, 2023. These data will no longer be updated after May 2023.

Vaccination status: A person vaccinated with at least a primary series had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after verifiably completing the primary series of an FDA-authorized or approved COVID-19 vaccine. An unvaccinated person had SARS-CoV-2 RNA or antigen detected on a respiratory specimen and has not been verified to have received COVID-19 vaccine. Excluded were partially vaccinated people who received at least one FDA-authorized vaccine dose but did not complete a primary series ≥14 days before collection of a specimen where SARS-CoV-2 RNA or antigen was detected. A person vaccinated with a primary series and a monovalent booster dose had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after verifiably receiving a primary series of an FDA-authorized or approved vaccine and at least one additional dose of any monovalent FDA-authorized or approved COVID-19 vaccine on or after August 13, 2021. (Note: this definition does not distinguish between vaccine recipients who are immunocompromised and are receiving an additional dose versus those who are not immunocompromised and receiving a booster dose.) A person vaccinated with a primary series and an updated (bivalent) booster dose had SARS-CoV-2 RNA or antigen detected in a respiratory specimen collected ≥14 days after verifiably receiving a primary series of an FDA-authorized or approved vaccine and an additional dose of any bivalent FDA-authorized or approved vaccine COVID-19 vaccine on or after September 1, 2022. (Note: Doses with bivalent doses reported as first or second doses are classified as vaccinated with a bivalent booster dose.) People with primary series or a monovalent booster dose were combined in the “vaccinated without an updated booster” category.

Deaths: A COVID-19–associated death occurred in a person with a documented COVID-19 diagnosis who died; health department staff reviewed to make a determination using vital records, public health investigation, or other data sources. Per the interim guidance of the Council of State and Territorial Epidemiologists (CSTE), this should include persons whose death certificate lists COVID-19 disease or SARS-CoV-2 as the underlying cause of death or as a significant condition contributing to death. Rates of COVID-19 deaths by vaccination status are primarily reported based on when the patient was tested for COVID-19. In select jurisdictions, deaths are included that are not laboratory confirmed and are reported based on alternative dates (i.e., onset date for most; or date of death or report date, where onset date is unavailable). Deaths usually occur up to 30 days after COVID-19 diagnosis.

Participating jurisdictions: Currently, these 24 health departments that regularly link their case surveillance to immunization information system data are included in these incidence rate estimates: Alabama, Arizona, Colorado, District of Columbia, Georgia, Idaho, Indiana, Kansas, Kentucky, Louisiana, Massachusetts, Michigan, Minnesota, Nebraska, New Jersey, New Mexico, New York, New York City (NY), North Carolina, Rhode Island, Tennessee, Texas, Utah, and West Virginia; 23 jurisdictions also report deaths among vaccinated and unvaccinated people. These jurisdictions represent 48% of the total U.S. population and all ten of the Health and Human Services Regions. This list will be updated as more jurisdictions participate.

Incidence rate estimates: Weekly age-specific incidence rates by vaccination status were calculated as the number of cases or deaths divided by the number of people vaccinated with a primary series, overall or with/without a booster dose (cumulative) or unvaccinated (obtained by subtracting the cumulative number of people vaccinated with at least a primary series and partially vaccinated people from the 2019 U.S. intercensal population estimates) and multiplied by 100,000. Overall incidence rates were age-standardized using the 2000 U.S. Census standard population. To estimate population counts for ages 6-12 months, half of the single-year population counts for ages <12 months were used. All rates are plotted by positive specimen collection date to reflect when incident infections occurred.

Continuity correction: A continuity correction has been applied to the denominators by capping the percent population coverage at 95%. To do this, we assumed that at least 5% of each age group would always be unvaccinated in each jurisdiction. Adding this correction ensures that there is always a reasonable denominator for the unvaccinated population that would prevent incidence and death rates from growing unrealistically large due to potential overestimates of vaccination coverage.

Incidence rate ratios (IRRs): IRRs for the past one month were calculated by dividing the average weekly incidence rates among unvaccinated people by that among people vaccinated without an updated (bivalent) booster dose) or vaccinated with an updated (bivalent) booster dose.

Archive: An archive of historic data, including April 3, 2021-September 24, 2022 and posted on October 21, 2022 is available on data.cdc.gov. The analysis by vaccination status (unvaccinated and at least a primary series) for 31 jurisdictions is posted here: https://data.cdc.gov/Public-Health-Surveillance/Rates-of-COVID-19-Cases-or-Deaths-by-Age-Group-and/3rge-nu2a. The analysis for one booster dose (unvaccinated, primary series only, and at least one booster dose) in 31 jurisdictions is posted here: https://data.cdc.gov/Public-Health-Surveillance/Rates-of-COVID-19-Cases-or-Deaths-by-Age-Group-and/d6p8-wqjm. The analysis for two booster doses (unvaccinated, primary series only, one booster dose, and at least two booster doses) in 28 jurisdictions is posted here: https://data.cdc.gov/Public-Health-Surveillance/Rates-of-COVID-19-Cases-or-Deaths-by-Age-Group-and/ukww-au2k.

References

Scobie HM, Johnson AG, Suthar AB, et al. Monitoring Incidence of COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Status — 13 U.S. Jurisdictions, April 4–July 17, 2021. MMWR Morb Mortal Wkly Rep 2021;70:1284–1290.

Johnson AG, Amin AB, Ali AR, et al. COVID-19 Incidence and Death Rates Among Unvaccinated and Fully Vaccinated Adults with and Without Booster Doses During Periods of Delta and Omicron Variant Emergence — 25 U.S. Jurisdictions, April 4–December 25, 2021. MMWR Morb Mortal Wkly Rep 2022;71:132–138

Johnson AG, Linde L, Ali AR, et al. COVID-19 Incidence and Mortality Among Unvaccinated and Vaccinated Persons Aged ≥12 Years by Receipt of Bivalent Booster Doses and Time Since Vaccination — 24 U.S. Jurisdictions, October 3, 2021–December 24, 2022. MMWR Morb Mortal Wkly Rep 2023;72:145–152

Studies examining factors responsible for COVID-19 incidence are mostly focused at the national or sub-national level. A global-level characterization of contributing factors and temporal trajectories of disease incidence is lacking. Here we conducted a global-scale analysis of COVID-19 infections to identify key factors associated with early disease incidence. Additionally, we compared longitudinal trends of COVID-19 incidence at a per-country level and classified countries based on COVID-19 incidence trajectories and effects of lockdown responses. Univariate analysis identified eleven variables as independently associated with COVID-19 infections at a global level (p<1e-05). Multivariable analysis identified a 4-variable model as optimal for explaining global variations in COVID-19 (p<0.01). COVID-19 case trajectories for most countries were best captured by a log-logistic model, as determined by AIC estimates. Six predominant country clusters were identified when characterizing the effects of lockdown intervals on variations in COVID-19 new cases per country. Globally, economic and meteorological factors are important determinants of early COVID-19 incidence. Analysis of longitudinal trends and lockdown effects on COVID-19 highlights important nuances in country-specific responses to infections. These results provide valuable insights into disease incidence at a per-country level, possibly allowing for more informed decision making by individual governments in future disease outbreaks. Methods Data for COVID-19 confirmed cases was obtained from https://ourworldindata.org/coronavirus-source-data, which is updated daily and based on data on confirmed cases and deaths from Johns Hopkins University. Data on additional demographic, meteorological, health or economic variables were downloaded from a variety of sources online. For each variable, values from the most recent year for which data on the greatest number of countries were available were utilized (varied between 2016-2019). Variables were categorized as Demographic, Meterological, Health or Economic domains. Please see the README document ("README_data_COVID19_112322.txt") and the accompanying published article: Ghosh, S., Roy, S.S. Global-scale modeling of early factors and country-specific trajectories of COVID-19 incidence: a cross-sectional study of the first 6 months of the pandemic. BMC Public Health 22, 1919 (2022). https://doi.org/10.1186/s12889-022-14336-w

This dataset comprises new and accumulated cases and death episodes for each Brazilian municipality, by epidemiological week.

Criteria for confirmed cases: * Final classification (variable CLASSI_FIN) = 5 * Antigenic test result (variable AN_SARS2) = 1 * RT-PCR test result (variable AN_SARS2) = 1 For death episodes: * confirmed cases that progressed to death (variable EVOLUCAO = 2) * death from other causes (variable EVOLUCAO = 3) Reference date for cases: * symptom onset date (variable DT_SIN_PRI) Reference date for death episodes: * case evolution date (variable DT_EVOLUCA) * for missing dates, the closest date was used: case closing date, ICU discharge date, ICU entry date, testing date, notification date Age groups follow a five-years interval Phase and peak variables were created based on epidemiological weeks.

This dataset was used as part project - Evaluating Effects of Social Inequalities on the COVID-19 Pandemic in Brazil. Maria Yury Ichihara and colleagues at the Centre for Data and Knowledge Integration for Health (Cidacs) at Fiocruz in Brazil created a social disparities index to measure inequalities relevant to the COVID-19 pandemic, such as unequal access to healthcare, to identify regions that are more vulnerable to infection and to better focus prevention efforts.

In Brazil, markers of inequality are associated with COVID-19 morbidity and mortality. They developed the index with available COVID-19 surveillance data, hosted on the Cidacs platform, and built a public data visualisation dashboard to share the index and patterns of COVID-19 incidence and mortality with the broader community. This enabled health managers and policymakers to monitor the pandemic situation in the most vulnerable populations and target social and health interventions.

Permissions to use this dataset must be obtained from the Ministry of Health Brazil.